Pronulife® GlucoCtrl

• Better efficacy
• Stronger immunity
• Shorter recovery time
• Function: Glucose Control

Type 1 Diabetes

• Type 1 diabetes, also known as "insulin-dependent diabetes," is an autoimmune disease resulting from damaged pancreatic β-cells, leading to insufficient insulin production.
• It affects 5-10% of diabetes cases and usually develops in childhood or adolescence.
• Unfortunately, it cannot be cured, requiring lifelong insulin injections for treatment, and it can have long-term effects on overall health and other organs.

Gut Microbiota and Glucose Metabolism

• Imbalanced gut microbiota disrupts metabolism, affecting blood sugar regulation.
• In autoimmune disease patients, Bacteroidota bacteria associated with metabolism and obesity increase, while Bacillota bacteria (formerly Firmicutes), which strengthen the gut barrier, decrease.
• Reduced butyrate-producing bacteria in type 1 diabetes patients impact mucus synthesis and intestinal integrity, allowing microbial antigens to trigger autoimmune diseases.
• Gut microbiota changes, dietary habits, and inflammatory fluctuations influence metabolism.
• The gut microbiome modulates blood sugar metabolism through SCFAs produced by probiotics and incretins secreted by gut cells, vital in regulating glucose metabolism.

• R&D Center has selected powerful probiotic strains (Bifidobacterium animalis subsp. lactis CP-9, Lactobacillus johnsonii MH-68, and Lactobacillus salivarius AP-32) known for their effective blood sugar control in type 1 diabetes.
• Studies have shown that Lactobacillus salivarius AP-32 and Lactobacillus reuteri GL-104 protect β-cells, stabilize blood sugar, and improve liver and kidney functions affected by diabetes.
• Clinical research demonstrates that Pronulife® GlucoCtrl probiotics improve glycated hemoglobin levels, stabilize blood sugar, reduce inflammatory hormones, and enhance anti-inflammatory hormones.
• NGS analysis reveals increased abundance of beneficial gut bacteria.